Growth Analyser Growth Analyser

Compare funds

Pick up to 10 funds. Compare funds from the same category for a fair reading.

Nippon India Pharma Fund · Direct ✕Aditya Birla Sun Life Pharma and Healthcare Fund · Direct ✕

Growth of ₹10,000

Basics

Nippon India Pharma FundAditya Birla Sun Life Pharma and Healthcare Fund
CategorySectoral / ThematicSectoral / Thematic
PlanDirectDirect
Fund houseNippon IndiaABSL
NAV₹666.3420₹41.5400
NAV date20 Nov 202620 Nov 2026
History13.9 years7.4 years
Expense ratio1.0%1.0%
Stars★★★★★★★★★★
Growth Score75.2080.50

Returns

Nippon India Pharma FundAditya Birla Sun Life Pharma and Healthcare Fund
1 month+11.40%+10.45%
3 months+3.74%+2.06%
6 months+8.55%+11.10%
YTD+16.94%+22.61%
1 year+15.26%+21.04%
3 years (CAGR)+17.96%+20.35%
5 years (CAGR)+15.40%+16.19%
10 years (CAGR)+16.61%—
Since launch+17.63%+21.24%

Risk

Nippon India Pharma FundAditya Birla Sun Life Pharma and Healthcare Fund
Volatility14.1%14.6%
Downside volatility9.0%8.5%
Sharpe0.810.95
Sortino1.281.63
Calmar1.221.28
Return / risk1.271.39
Deepest fall−24.02%−20.46%
Days to recover445398
Below its high+0.00%−0.02%

Against benchmark

Nippon India Pharma FundAditya Birla Sun Life Pharma and Healthcare Fund
Alpha−1.86%−0.50%
Beta0.890.94
R²89.5%93.0%
Up capture85.2%92.2%
Down capture88.7%90.9%
Tracking error4.8%3.9%
Information ratio−0.69−0.34
Treynor0.120.14

Consistency

Nippon India Pharma FundAditya Birla Sun Life Pharma and Healthcare Fund
Best 1-year+90.70%+72.90%
Middle 1-year+13.13%+18.02%
Worst 1-year−15.12%−15.55%
1-year periods with a loss23.2%19.4%
Middle 3-year+19.82%+19.92%
Positive months63.9%61.1%
Best day+3.40%+3.23%
Worst day−3.21%−2.91%
Worst 5% day−1.38%−1.28%
Positive days53.7%54.9%
NAVs a year247247

SIP of ₹10,000 a month

Nippon India Pharma FundAditya Birla Sun Life Pharma and Healthcare Fund
5-year XIRR+18.24%+19.85%
5-year value₹9,54,076₹9,93,026
3-year XIRR+14.26%+16.84%
1-year XIRR+22.08%+26.66%

Holdings overlap i

Overlap needs the monthly portfolio filing of at least two of these funds; not loaded yet.

Search Growth